Performance Analysis of Deep-Neural-Network-Based Automatic Diagnosis of Diabetic Retinopathy.
Hassan TariqMuhammad RashidAsfa JavedEeman ZafarSaud S AlotaibiMuhammad Yousuf Irfan ZiaPublished in: Sensors (Basel, Switzerland) (2021)
Diabetic retinopathy (DR) is a human eye disease that affects people who are suffering from diabetes. It causes damage to their eyes, including vision loss. It is treatable; however, it takes a long time to diagnose and may require many eye exams. Early detection of DR may prevent or delay the vision loss. Therefore, a robust, automatic and computer-based diagnosis of DR is essential. Currently, deep neural networks are being utilized in numerous medical areas to diagnose various diseases. Consequently, deep transfer learning is utilized in this article. We employ five convolutional-neural-network-based designs (AlexNet, GoogleNet, Inception V4, Inception ResNet V2 and ResNeXt-50). A collection of DR pictures is created. Subsequently, the created collections are labeled with an appropriate treatment approach. This automates the diagnosis and assists patients through subsequent therapies. Furthermore, in order to identify the severity of DR retina pictures, we use our own dataset to train deep convolutional neural networks (CNNs). Experimental results reveal that the pre-trained model Se-ResNeXt-50 obtains the best classification accuracy of 97.53% for our dataset out of all pre-trained models. Moreover, we perform five different experiments on each CNN architecture. As a result, a minimum accuracy of 84.01% is achieved for a five-degree classification.
Keyphrases
- convolutional neural network
- diabetic retinopathy
- deep learning
- neural network
- editorial comment
- optical coherence tomography
- machine learning
- end stage renal disease
- chronic kidney disease
- type diabetes
- endothelial cells
- newly diagnosed
- healthcare
- peritoneal dialysis
- cardiovascular disease
- resistance training
- oxidative stress
- computed tomography
- gene expression
- adipose tissue
- weight loss
- patient reported outcomes
- mass spectrometry
- genome wide
- high intensity